Erdafitinib for FGFR-mutated urothelial carcinoma
Orphan drugs and other treatment options for Merkel cell carcinoma
Pembrolizumab: defining standards of care in urothelial cancer
Immunotherapy: changing the landscape of cancer treatment
Drugs with low response rates - should they always be offered to patients?